A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for Wegovy and Zepbound ...

A decision by CMS to not move forward with a proposed rule allowing obesity medications to be covered under Medicare Part D ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Democrat senators are begging Health and Human Services Secretary (HHS) Robert F. Kennedy Jr. to keep a proposed Biden-era rule pertaining to obesity drugs. In November, the […] ...

On April 4, 2025, the Centers for Medicare & Medicaid Services (“CMS”) released the contract year (“CY”) 2026 final rule for the Medicare ...

The Biden administration sought to sidestep this obstacle by issuing a rule in November reinterpreting existing statutes to allow for Medicare Part D to cover anti-obesity drugs. But earlier this ...